| Literature DB >> 36034846 |
Gul-E-Saba Chaudhry1, Abdah Md Akim2, Yeong Yik Sung1, Tengku Muhammad Tengku Sifzizul1.
Abstract
Cancer is a multifactorial, multi-stage disease, including complex cascades of signaling pathways-the cell growth governed by dysregulated and abrupt cell division. Due to the complexity and multi-regulatory cancer progression, cancer is still a challenging disease to treat and survive. The screening of extracts and fractions from plants and marine species might lead to the discovery of more effective compounds for cancer therapeutics. The isolated compounds and reformed analogs were known as future prospective contenders for anti-cancer chemotherapy. For example, Taxol, a potent mitotic inhibitor discovered from Taxus brevifolia, suppresses cell growth and arrest, induces apoptosis, and inhibits proliferation. Similarly, marine sponges show remarkable tumor chemo preventive and chemotherapeutic potential. However, there is limited research to date. Several plants and marine-derived anti-cancer compounds having the property to induce apoptosis have been approved for clinical trials. The anti-cancer activity kills the cell and slows the growth of cancer cells. Among cell death mechanisms, apoptosis induction is a more profound mechanism of cell death triggered by naturally isolated anti-cancer agents. Evading apoptosis is the major hurdle in killing cancer cells, a mechanism mainly regulated as intrinsic and extrinsic. However, it is possible to modify the apoptosis-resistant phenotype of the cell by altering many of these mechanisms. Various extracts and fractions successfully induce apoptosis, cell-cycle modulation, apoptosis, and anti-proliferative activity. Therefore, there is a pressing need to develop new anti-cancer drugs of natural origins to reduce the effects on normal cells. Here, we've emphasized the most critical elements: i) A better understanding of cancer progression and development and its origins, ii) Molecular strategies to inhibit the cell proliferation/Carcino-genesis, iii) Critical regulators of cancer cell proliferation and development, iv) Signaling Pathways in Apoptosis: Potential Targets for targeted therapeutics, v) Why Apoptosis induction is mandatory for effective chemotherapy, vi) Plants extracts/fractions as potential apoptotic inducers, vii) Marine extracts as Apoptotic inducers, viii) Marine isolated Targeted compounds as Apoptotic inducers (FDA Approved/treatment Phase). This study provides a potential therapeutic option for cancer, although more clinical studies are needed to verify its efficacy in cancer chemotherapy.Entities:
Keywords: apoptosis; apoptotic inducers; cancer; marine drug; natural product; targeted therapeutic
Year: 2022 PMID: 36034846 PMCID: PMC9399632 DOI: 10.3389/fphar.2022.842376
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1The process of cancer development/carcinogenesis, (A) Cancer initiation (B). Cancer Progression (C). Metastasis and Cancer development. Created with BioRender.com.
FIGURE 2Targeting regulators in inhibition of cell progression. It is mainly divided into apoptosis regulators and others. Targeting Apoptosis includes i) up-regulation of pro-apoptotic (caspases protein, Bax, and pro-apoptotic member of Bcl-2 family) ii) down-regulation of anti-apoptotic proteins (IAPs). Also, by targeting the pro-survival signaling pathways, invasion and metastasis proteins dysregulated in cancer cells, created with BioRender.com.
FIGURE 3Apoptosis pathways. Apoptosis has two primary routes known as the i) extrinsic and ii) intrinsic pathway. First, external stimuli or ligand molecules activate the transduction, including death receptors (SDRs), leading to caspase 3/7 activation via/or activated caspase 8. Intrinsic pathway; via insertion of proapoptotic molecules BAX (protein) into the mitochondrial membrane results in the generation of cytochrome c, forming an apoptosome, which further triggers the apoptotic cascades beginning with proapoptotic activation caspase 9 and or then caspase 3. Created with BioRender.com.
Plant extracts/fractions as apoptotic inducers for breast cancer (in vitro). updated and improved from (Israels and Israels, 2000).
| Plant name | Extract/Fraction | Part used | Growth inhibition conc (μg/ml) | Target cell lines | Mechanism of cell death | References |
|---|---|---|---|---|---|---|
| Allium atroviolaceum | Methanolic Extract | Flower | 500 μg/ml (70% GI) | MCF-7, MDA-MB-231 | - Induces apoptosis |
|
| - Modulating Cell Cycle Arrest | ||||||
| - Caspase-Dependent and p53-Independent Pathway | ||||||
| Phaseolus vulgaris (black turtle bean) | Extract | Seeds | 50 μg/ml | MCF-7 and MDA-MB231 | - Upregulation of Bax and downregulation of Bcl-2 and Bcl-xL |
|
| - Activation of caspase -3/7 | ||||||
| Ganoderma lucidum | Ethanol extract | Chipped fruiting bodies | 234 μg/ml | MCF-7 | - Induces cell cycle arrest and apoptosis -Up‐regulation of p21/Waf1 and down‐regulation of cyclin D1 |
|
| - Up‐regulation of pro‐apoptotic Bax protein | ||||||
| Echinophora Platyloba | Methanol Extract | Leaves | 25 μg/ml | MDA-MB-231 | - Induces Apoptosis and Cell Cycle Arrest at S-Phase |
|
| - Up-regulation of bax and p27 | ||||||
| - Down-regulation of bcl-2 | ||||||
| Morinda Citrifolia | Ethyl-acetate extract | Fruit | 25 μg/ml | MCF-7, MDA-MB-231 | - Arrested the cell cycle in the G1/S phase in MCF-7 and G0/G1 phase in MDA-MB-231 cells |
|
| - Downregulation of intracellular “ROS” and “mitochondrial membrane potential” | ||||||
| Fragaria ananassa Strawberry | Methanolic extract | Fruit | NA | T-47D | - Cleavage of MCL-1 |
|
| - downregulation of BCL-xL | ||||||
| - Upregulation of expression of proapoptotic proteins such as BAX and BID | ||||||
| - Upregulation of p73 | ||||||
| - Activation of Caspase 3 and Caspase 9 | ||||||
| Vatica diospyroides | Acetone and methanolic extracts | Fruit | 1.60–17.45 μg/ml | MDA-MB-468 | - Induces “apoptosis” |
|
| - “Up-regulation of Bax” | ||||||
| Averrhoa Bilimbi | Methanolic extract | Fruit, Leaves | NA | MCF-7 | - Anticancer Activity |
|
| Carica papaya L | Aqueous Extract | Leaves | 1319.25 μg/ml | MCF-7 | - “Anti-proliferation” and “Apoptosis” Induction |
|
| Mimosa caesalpiniifolia | Ethanolic extract | Leaf | 5.0 μg/ml | MCF-7 | - Induces apoptosis |
|
| - “DNA fragmentation” | ||||||
| Annona muricata | Aqueous extract | Leaves | NA | MCF-7, MDA-MB-231 | - Induces apoptosis |
|
| Acanthopanax sessiliflorus | Hexane fraction | Stem bark | 53.46 μg/ml 58.40 μg/ml | MDA-MB-231 and MCF-7 | - “Non-apoptotic cell death” via mitochondria associated with both ROS dependent and independent pathways |
|
| Phaleria macrocarpa | Ethyl acetate fraction | Fruit | 18.10 μg/ml | MDA-MB-231 | - Induce G0/G1 and G2/M cell cycle arrest |
|
| - Activation of caspase -8,9 and 3 | ||||||
| - Upregulation of Bax, Bid | ||||||
| - cytochrome c, p21, p27, p53 and SMAC | ||||||
| - Downregulation of Bcl-2, Bcl-w, XIAP and survivin | ||||||
| Stryphnodendron adstringens | Aqueous extract fraction | Leaves | 76.31 μg/ml 186.83 μg/ml | MCF-7, MDA-MB-435 | - Upregulation of Bax, caspase-9, active caspase-3, caspase-8, LC-3, and beclin-1 |
|
| - Downregulation of Bcl-2 | ||||||
| Avicennia Marina | Crude methanol extract and fraction | Leaves | 250 μg/ml | MDA-MB 231 | - DNA fragmentation. |
|
| - Decreased mRNA expression level of Bcl-2 and increased p53 | ||||||
| Salvia chloroleuca | Hexane and methylene chloride fractions | Roots | 25.49–60.25 μg/ml | MCF-7 | - Induced a sub-G1 peak |
|
| - DNA fragmentation | ||||||
| - ROS-mediated pathway | ||||||
| Scrophularia oxysepala | Methanolic subfractions | Aerial parts | 52.9–61.2 μg/ml | MCF-7 | - Activation of caspase-3 |
|
| - Downregulation of Bcl-2 | ||||||
| Artocarpus altilis | Diethyl ether extract | Wood | 6.19 μg/ml | T-47D | - Induced apoptosis and sub-G1 phase formation |
|
| Piper crocatum | Methanol extract | Leaves | 44.25 μg/ml | T-47D | - Inhibition of p44/p42 phosphorylation |
|
| Pistacia atlanticasub kurdica | Methanol | Fruits skin | 1 mg/ml | T-47D | 1. Activation of caspase 3 |
|
| 2. Poly ADP ribose polymerase (PARP) cleavage | ||||||
| Vitex rotundifolia | Extract/fraction | leave | 6.30–63.09 μg/ml | MCF-7 | 1. Extrinsic and intrinsic pathway both activated |
|
| Vitex rotundifolia | fraction | leave | 10-79.43 μg/ml | T47D | 2. Extrinsic and intrinsic pathway both activated |
|
| Vitex negundo | Aqueous and Ethanolic extract | Leaves | 200–300 μg/ml | MCF-7 | 3. Induced apoptosis |
|
| Jatropha curcas | Ethanol extract | Root bark | 36.55 μg/ml | MCF-7 | 4. Inducing anoikis |
|
| Vernonia amygdalina | Ethanol extract | Leaves | 46–56 μg/ml | MCF-7 and MDA-MB-231 | 5. Induced apoptosis |
|
| 6. G1/S phase cell cycle arrest | ||||||
| 7. Caspase-dependent | ||||||
| Strobilanthes crispa | Hexane extract | Stem | 42.5 μg/ml | MDA-MB-231 | 1. Induced apoptosis |
|
| Ixeris dentata | Methanol extract | - | 100–200 μg/ml | T-47D, MCF-7, SK-BR-3, and MDA-MB-231 | - Induced apoptosis |
|
| - | ||||||
| Tinospora cordifolia | Chloroform fraction | Stems | 28.09–35.06 μg/ml | MCF-7 and MDA-MB-231 | 1. ROS mediated apoptosis |
|
| Smilax china | Ethanol extract | Bark | NA | MDA-MB-231 | 2. Suppression of metastasis |
|
| 3. “Modulation of uPA, uPAR and TIMP expression” | ||||||
| Bauhinia ungulata | Different fractions | Stem | 23.47 µg/mL | 4T1 | 4. Anti-tumor |
|
| 5. Antimetastatic | ||||||
| 6. Decreasing the MMP-2 activity | ||||||
| 157Nicotiana glauca | Dichloromethane fraction | Stem | 17.98 μg/ml | MCF-7 | - Anti-Metastatic |
|
| Euphorbia humifusa | Ethyl acetate fraction | Whole plant | 5 μg/ml | MDA-MB-231 | 7. Inhibition of NF-κB activity |
|
| 8. Induced matrix metalloproteinase (MMP)-9 mRNA expression | ||||||
| Withania coagulans | Ethyl acetate | Aerial with fruit | NA | MCF-7, MDA-MB-231 | - Inhibited TNF-α induced NFκB activity |
|
| Astragalus membranaceus | Water- ethanol extract | Roots | NA <100 μg/ml | MCF-7, SK-BR-3, and MDA-MB-231 | - Anti-proliferative |
|
| - Induced apoptosis | ||||||
| - Inhibition of PI3K/AKT/mTOR signaling pathway | ||||||
| Dillenia suffruticosa | Ethyl acetate extract | Roots | 36 μg/ml | MCF-7 | - “Induces apoptosis via inhibition of AKT and ERK”, and activation of JNK |
|
| Catharanthus roseus | Methanol extract | Leaves | > 200 μg/ml. | MDA-MB-231 | - Anti-invasive |
|
| - Suppressed the MMP-2 and MMP-9 activity | ||||||
| Forsythia koreana | Methanol extract | Fruit and leaves | NA | MDA-MB-231 | - “Suppressed invasion and MMPs activities” |
|
| - Inhibited the receptor activator of nuclear factor kappa-B | ||||||
| Origanum majorana | Ethanolic extract | Leaves | NA | MDA-MB-231 | - “Anti-invasive and anti-metastatic |
|
| - Downregulates the phosphorylation of IκB, nuclear level of NFκB and Nitric Oxide (NO) production” | ||||||
| Brassica oleracea | Extract | - | NA | MDA-MB-231 | - Anti-invasive |
|
| - Suppressed TPA-induced MMP-9 activity | ||||||
| Salvia triloba | Ethanolic crude extracts | Whole plant | NA | MCF 7 | - Antiangiogenesis |
|
| - Inhibited the expression of VEGF at the mRNA and protein level | ||||||
| Eugenia jambolana | Ethyl acetate fractions | Seeds | 25 μg/ml | MCF-7, MDA-MB-231 | - Suppression of VEGF-induced angiogenesis |
|
| Musa paradisiaca | Ethyl acetate fractions | Roots | 60 μg/ml | MCF-7,MDA-MB-231 | - Suppression of VEGF-induced angiogenesis |
|
| Buxus sempervirens | Acetonic extract | Leaves and flowers | 7.74–12.5 μg/ml | MCF7, T47D, MCF10CA1a, and BT-20 | - Induces apoptosis |
|
| - Cell cycle arrest, Autophagy | ||||||
| Cucurbita ficifolia | Chloroform | Fruit | 90 μg/ml | MCF-7 | - FADD; BAK; BAX; caspase-3, -9, and -8 Increased |
|
| Cyperus rotundus L. | Ethanol | Rhizome | 200 μg/ml | MDA-MB-231 | - Upregulation: Bax; DR5; activation of Bid; activation of caspase-3, -9, and -8 downregulation: Bcl-2; survivin; MMP |
|
| Euphorbia hirta L. | Methanol | Whole plant | 25.26 μg/ml | MCF-7 | - Activation of caspase-2, -6, -8, -9, and -3 Increased |
|
| Oldenlandia diffusa | Methanol and butanol | Whole plant | 0–20 μg/ml | MCF-7 | - Bax; activation of caspase-8 and -7 Increased and down regulation Bcl-2 |
|
Marine (sponges) extracts/fractions as apoptotic inducers for various cancer cell lines (in vitro). Improved and updated from (Shin et al., 2017) (Calcabrini et al., 2017).
| Marine species | Cell line | Conc. Range IC50 (μM)/μg/mL) | Phosphatidylserine externalization (PS) (initial apoptosis) | DNA fragmentation (late Apoptosis) | Caspase activation | PARP cleavage | References |
|---|---|---|---|---|---|---|---|
|
| MCF-7 | 5.0–25.00 μg/ml | √ | √ |
| ||
|
| MCF-7 | 8.49 μg/ml | √ | √ |
| ||
| 7.61 μg/ml | |||||||
| 21.88 μg/ml | |||||||
| 97.72 μg/ml | |||||||
|
| HeLa | 6.71–8.54 μg/ml | √ | √ |
| ||
|
| HeLa | 14.76–2.54 μg/ml | √ | √ |
| ||
|
| MCF-7 | 3.39–37.15 μg/ml | √ | √ |
| ||
|
| HeLa | 0–18.93 μg/ml | √ |
| |||
|
| HeLa | 0–30 μg/ml | √ |
| |||
|
| HeLa, HepG2 | 0.22–74.13 μg/ml | √ |
| |||
|
| THP-1 | 50–200 μM | √ |
| |||
|
| THP-1 | 10–25 μM | √ |
| |||
|
| THP-1 | 10–25 μM | √ |
| |||
|
| AsPC-1 | 2.4 | μM | √ | 3 and 7 |
| |
| BxPC-3 | 2.4 | μM | √ | 3 and 7 | |||
| PANC-1 | 2.4 μM | √ | 3 and 7 | ||||
|
| Raji | 50 | √ | 3 and 7 | √ |
| |
| U937 | 50 μM | √ | √ | ||||
|
| AsPC-1 | 6.8 μM | √ | 3 and 7 |
| ||
|
| PANC-1 | 6.8 μM | √ | 3 and 7 |
| ||
|
| MIA PaCa-2 | 6.8 μM |
| ||||
|
| BxPC-3 | 6.8 μM |
| ||||
|
| MDA-MB-435 | 0.1 μM | 3 |
| |||
|
| HeLa | 10 μg/ml | 3 |
| |||
| T47D | |||||||
|
| U251 HCT116 | 0.05–0.10 μM | √ | 3 and 12 |
| ||
|
| HL-60 | 31.0–77.5 μM | √ |
| |||
|
| HepG2 | 0.5–2.5 μM | √ | 3 |
| ||
|
| HepG2 | 0.5–2.5 μM | √ | 3 |
| ||
|
| HepG2 | 0.5–2.5 μM | √ | 3 |
| ||
|
| U937 HL-60 | 5–15 μM | √ |
| |||
|
| Hep3B | 0.01 μg/ml | √ | 3, 8, and 9 |
| ||
|
| U937 | 0.008–0.010 μg/mL | √ | √ | 3 | √ |
|
|
| K562 normoxic and hypoxic conditions | 0.01–0.2 μM | √ | 3 and 9 |
| ||
|
| Hela | 10 μg/ml | √ | 3 |
| ||
| T47D | 10 μg/ml | ||||||
|
| CA46, Ramos, Daudi, HL-60, MDA-MD-231, MCF-7, HCT-116, HT-29 | 0.1 μM | √ |
| |||
|
| HL-60 | 1.6–25 μg/ml | √ | √ | 3 |
| |
| HT-29 | 5–30 μM | √ | |||||
|
| HL-60 | 4 μg/ml | 3 |
| |||
|
| HCT116 | 2.5–10 μM | √ | √ | 3 and 8 |
| |
| PC-3 | 2–10 μM | √ |
| ||||
|
| MCF-7 | 0.0002–0.0005 μM | √ | 2,5,7,8, 9 |
| ||
|
| Jurkat | 0.0002 μM | √ | 2, 3, 7, 8 ,and 9 |
| ||
| L3.6pL | 0.00001–0.01 μM | √ |
| ||||
|
| K562 | 1.4–5.6 μM | √ | 3, 8, and 9 | |||
| DU145 | 0.01–1 μg/ml | √ | 3, 8, and 9 |
| |||
| PC-3 | 0.01–1 μg/ml | √ | 3, 8, and 9 |
| |||
| LNCaP | 0.01 μg/ml | √ | |||||
| T24 | 0.1–0.8 μg/ml | √ | √ | 3 and 9 |
| ||
| A498 | 0.5–3 μM | √ | 3, 8 and 9 |
| |||
|
| HUVEC | 0.01–1 μM | √ | 3 and 7 |
| ||
|
| Jurkat | 0.01 μM | √ | 3, 8 and 9 |
| ||
|
| Bel-7402 | 0.5 μM | √ |
| |||
| HepG2 | 10–20 μM | ||||||
|
| K562 | 0.012–0.054 μM | √ | 3 and 9 | √ |
| |
| A549 | 0.02–1 μM | √ | 3 and 7 | √ | |||
| SF295 | 0.04–1 μM | √ | √ | ||||
|
| B16 | 5 μM | √ | √ | 3 and 9 | √ |
|
| HaCaT | 5 μg/ml | 3 | |||||
|
| HL-60 | 19.9 μM | √ |
| |||
|
| HL-60 | 21.3 μM | √ |
| |||
|
| HL-60 | 21.5 μM | √ |
| |||
|
| AsPC-1 | 0.01 μM | √ |
| |||
| BxPC-3 | 0.01 μM | √ | 3 | ||||
| MIA PaCa-2 | √ | 3 | |||||
|
| √ | 3, 8 and 9 |
| ||||
|
| HeLa | 1.39–2.01 μM | √ | 3 and 7 |
| ||
|
| 32D | 0.1 μM |
| ||||
|
| MKN45 NUGC-4 | − 10 | √ | 3 and 7 |
| ||
| 0.01–10 μM | √ | ||||||
|
| MCF-7 | 0.5–2.5 μM | √ |
| |||
|
| SK-MEL-2 | 0.1–0.3 μg/ml | √ | 3 and 9 |
| ||
|
| Human endometrial Ishikawa | √ |
| ||||
|
| Ishikawa | 1 μM | √ |
| |||
| ECC1 | 1 μM | ||||||
|
| K562 | 7.7–30.8 μM | √ | 3 and 9 |
| ||
|
| HUVEC | 1–10 μM | 3 and 7 |
| |||
|
| HL-60 | √ | 3 | √ |
| ||
| HL-60 | 10–25 μM | √ | 3, 8 and 9 |
| |||
|
| HT-29 | 1–6 μM | √ | 3 |
| ||
| THP-1 | 1–10 μM | √ |
| ||||
| PC-3 | 0.5–4 μM | √ | 8 | ||||
| DU-145 | 0.5–4 μM | √ | 8 | ||||
| 22Rv1 | 0.5–4 μM | √ | 8 |
| |||
| VCaP | 0.5–4 μM | √ | 8 | ||||
|
| SK-MEL-2 | 25–50 μM | √ | 3 and 9 | √ |
| |
|
| HepG2 | 17.18 μM | √ | 3 |
| ||
| HCT-116 | 14.8 μM | √ | 3 | ||||
|
| HepG2 | 24 μM | √ | 3 |
| ||
| HCT-116 | 19.8 μM μM | √ | 3 | ||||
|
| Calu-1 | 0.05–0.1 μM | √ | √ |
| ||
|
| U937 | 17.2–103.3 μM | √ | √ | 3, 8 and 9 |
| |
|
| H460 | 5–40 μM | √ | 3 | √ |
| |
| U373MG | 0.0031 μM |
Marine base drugs (FDA Approved/treatment Phase) as Apoptotic inducers.
| Drug | Source (marine) | Mechanism of action | Progress status | Treatment for | Ref |
|---|---|---|---|---|---|
| Brentuximab2 vedotin (AdcetrisTM) | “Antibody-drug3 conjugate in a mixture of anti-CD30 antibody and monomethyl auristatin E (MMAE), obtained from sea hare Dollabella auricularia/cyanobacteria” | Blockage in cell cycle progression (G2 to M) induce “induction of apoptosis” | Approved by FDA (United States 2018); Also, phase III and I treatment of classical HL in a mixture using chemotherapy | “It is utilized for curing HL and chronic large cell anaplastic lymphoma” |
|
| Enfortumab vedotin | Cyanobacterium Caldora penicillata | By interaction with the microtubular network Arrest the cell cycle, and eventually apoptosis | Phase III | For Urothelial cancers |
|
| Marizomib | Actinomycete | “Act as apoptosis | Phase III | Used for “multiple |
|
| Salinispora tropica | Stimulants” and | myeloma and | |||
| “inhibits proteasome” | Glioblastoma” | ||||
| Polatuzumab | Cyanobacterium | As a apoptosis stimulants | Phase III | For the treatment |
|
| vedotin | Caldora penicillata | arrest mitosis | of diffuse large B cell | ||
| also tubulin | lymphoma | ||||
| inhibition micro-tubulin | |||||
| Polymerization | |||||
| GSK2857916 | Cyanobacterium | Apoptosis stimulant via | Phase II | Multiple myeloma |
|
| Caldora penicillata | “mitosis inhibitors tubulin | ||||
| polymerization inhibitors” | |||||
| Aplidine | Tunicate Aplidium | “Apoptosis stimulants”, cell | Phase II | “Multiple myeloma |
|
| plitidepsin | alpicans | cycle inhibitors protein | precursor cell | ||
| (Aplidin) | “synthesis inhibitors” | Lymphoblastic” | |||
| “vascular endothelial | leukemia-lymphoma | ||||
| growth factor receptor-1 | |||||
| Antagonists” | |||||
| Ladiratuzumab | Cyanobacterium | Apoptosis stimulants | Phase II | For Breast cancer |
|
| vedotin | Caldora penicillata | “mitosis inhibitors” | |||
| Glembatumumab | Cyanobacterium | Apoptosis stimulants | Phase-II | Brain cancer and Breast |
|
| vedotin | Caldora penicillata | mitosis inhibitors tubulin | osteosarcoma | ||
| Denintuzumab | Cyanobacterium | Act as “Immunomodulators” | uveal melanoma | ||
| mafodotin | Caldora penicillata | mitosis inhibitors also inhibitors of tubulin polymerization | Phase II | Diffuse large B-cell |
|
| (discontinued) | lymphoma | ||||
| Pinatuzumab | Cyanobacterium | Apoptosis stimulants | Phase I | Chronic lymphocytic |
|
| vedotin | Caldora penicillata | mitosis inhibitors tubulin | (discontinued) | leu emia diffuse large | |
| inhibitors tubulin | B cell lymphoma nHL | ||||
| polymerization inhibitors | |||||
| ASG-15ME | Cyanobacterium | Apoptosis stimulants | Phase I | Bladder cancer |
|
| Caldora penicillata | mitosis inhibitors tubulin | (discontinued) | urogenital cancer | ||
| inhibitors tubulin | |||||
| polymerization inhibitors | |||||
| CEP-2563 | Protein tyrosine kinase | Phase I | Solid tumors |
| |
| inhibitors | (discontinued) | ||||
| Lifastuzumab | Cyanobacterium | Apoptosis stimulants | Phase I | For various cancer Fallopian tube cancer |
|
| vedotin | Caldora penicillata | mitosis inhibitors tubulin | (discontinued) | non-small cell lung | |
| inhibitors tubulin | Cancer, ovarian cancer | ||||
| polymerization | Peritoneal cancer | ||||
| Vandortuzumab | Cyanobacterium | Apoptosis stimulants | Phase I | Prostate cancer |
|
| vedotin | Caldora penicillata | mitosis inhibitors | (discontinued) | ||
| polymerization inhibitors |